Nancy Lurker
CIK 1450485 · Executive Vice Chair · last filed 2026-05-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
EYPT price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
1 BURLINGTON ROAD
DUBLIN 4
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ALKS | Director | 18,222 | $45.90 | $836.4K | $0 | 7 | 2026-05-22 |
| COLL | Director | 26,758 | $24.21 | $647.8K | -$161.9K | 4 | 2026-05-18 |
| EYPT | Director | 421,235 | $0.36 | $151.6K | -$1.46M | 44 | 2026-01-07 |
| AQST | Director | — | $3.61 | — | $0 | 4 | 2021-06-17 |
| EyePoint, Inc. (PSDV) Delisted | President & CEO | 95,033 | — | — | $100.0K | 4 | 2018-03-21 |
| Keenova Therapeutics plc (MNK) Delisted | Director | 10,507 | $0.34 | $3.6K | $0 | 4 | 2016-03-18 |
| INTERPACE BIOSCIENCES, INC. (PDII) Delisted | CEO | 477,317 | — | — | $235.8K | 13 | 2015-03-09 |
| AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | Director | 0 | — | — | -$1.10M | 10 | 2015-01-30 |
Recent Filings · Page 3 of 11
101 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-04-14 | ALKS | Mixed | +4,616 | -$39.4K | EDGAR |
| 2025-02-11 | EYPT | Exer (M) | +20,000 | $0 | EDGAR |
| 2025-02-05 | COLL | Grant (A) | +12,726 | $0 | EDGAR |
| 2025-01-07 | EYPT | Mixed | +87,801 | $0 | EDGAR |
| 2024-08-20 | EYPT | Buy (P) | +3,173 | $25.0K | EDGAR |
| 2024-07-26 | EYPT | Gift (G) | — | $0 | EDGAR |
| 2024-07-12 | EYPT | Exer (M) | +11,111 | $0 | EDGAR |
| 2024-06-04 | ALKS | Grant (A) | — | $0 | EDGAR |
| 2024-04-12 | ALKS | Grant (A) | — | $0 | EDGAR |
| 2024-02-13 | EYPT | Mixed | +22,591 | -$430.4K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.